explore -WSS

explore

author：knowledge 2025-09-29 22:38:19 - browse：97

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Why the drug industry's warnings on the IRA's impact fall short

WSS

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Abbott's new stent may help patients with peripheral artery disease

WuXi Biologics beefs up its lobbying operation

The struggle to figure out which patients 'deserve' Wegovy

As H5N1 spreads in cows, experts warn against drinking raw milk

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Alkermes shareholders re

Transgender sports debate: Physicians say bans are health issue

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

DIEP, the 'gold standard' of breast reconstruction, is under threat

Boston hospital trains restaurant workers on naloxone for overdoses

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How the messy conversation about Dolly changed bioethics

At least 13 dead in Texas as scorching temps continue

Obesity drug from Roche shows promise in early study

leisure time

As H5N1 spreads in cows, experts warn against drinking raw milk

The White House hikes tariffs on plastic syringes made in China

Why the drug industry's warnings on the IRA's impact fall short

Why the drug industry's warnings on the IRA's impact fall short

People with substance use disorder deserve online privacy

Boston hospital trains restaurant workers on naloxone for overdoses

leisure time

explore

leisure time

focus